Recruiting

LCAT Deficiency

Sponsor:

University of Pennsylvania

Code:

NCT06217588

Conditions

LCAT Deficiency

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.

Study Details

Brief summary:

The purpose of the LCAT (Lecithin cholesterol acyl transferase) Natural History Study (LCAT NHS) is to help identify people with a mutation in a gene called LCAT, collect and store information about their medical history and disease course, and to assess for associations and follow changes in clinical features and biomarkers of disease. This information will help health care providers better understand the natural history of disease of LCAT deficiency.

Study staff will collect information from previous clinical visits such as lab tests, physical exam findings, renal and cardiovascular imaging, findings from kidney biopsies and eye exams, and medication and other treatments. As part of this study the investigators are asking participants permission to reach out to their doctors to obtain medical records and stored samples (such as serum or plasma or biopsies) from past visits.

Participants may also be asked to join a web-based patient portal to complete a patient-outcomes survey.

As part of this study, participants will also be asked to do the following things at different times:

  • Answer questions about:
  • Demographic information (year of birth, age, gender, race/ethnicity, country)
  • LCAT deficiency diagnosis such as year of diagnosis, type of diagnosis (clinical, genetic), genotype information/LCAT mutation status
  • Medical history and family history and any updates
  • A review of medications

If participants are able to come to a study visit in person the following may happen:

Physical examination including vital signs (height, weight, blood pressure, and heart rate) Urine and blood samples for laboratory testing. participants will be required to fast for 10 hours before the blood tests. A small blood sample may also be taken 2-4 hours after a meal.

  • The following will be tested: the different types of cholesterol and other fats in the blood (lipids), standard hematology (type and number of blood cells), blood chemistries such as sodium, potassium, and calcium, thyroid function, liver panel (function of the liver), kidney function and the level of protein in urine
  • Blood and urine samples may also be stored for future testing
  • Genetic material will be collected
  • Blood cells may be stored for future research
  • Participants will have approximately 4.5 tablespoons of blood drawn annually.
  • If not done previously, participants will complete an eye exam.
  • Participants may be seen by a doctor specialized in renal disease

Conditions

LCAT Deficiency

Study ID

NCT06217588

Start date

Aug 12, 2022

Status verified date

May, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Males or Females of any age
2. Subjects with:

1. a diagnosis of primary LCAT deficiency based on investigator assessment or laboratory results AND/OR
2. a genetically confirmed mutation in the LCAT gene who are homozygous or compound heterozygous for LCAT loss-of-function mutations
3. Subjects or their legal guardian must be able to comprehend and be willing to provide a signed institutional review board/ethics committee (IRB/EC) approved Informed Consent Form. A waiver of consent will be requested for deceased patients, as determined by local regulatory requirements.

Exclusion Criteria:

1. Secondary causes of LCAT deficiency
2. Any other medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Interventions

Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.

The study will collect extensive historical health data (retrospective), and at baseline will conduct an extensive characterization of the disease progression using the parameters described above.

Primary outcome measure

  • Reaching 40 Patients [ Time Frame: Through study completion, an average of 4 years ]
  • Mean Age of Diagnosis [ Time Frame: Through study completion, an average of 4 years ]
  • Average time to develop CKD (Chronic Kidney Disease) [ Time Frame: Through study completion, an average of 4 years ]

Central Contacts and Locations

Central contacts

Marina Cuchel, MD, PhD

2156627188mcuchel@pennmedicine.upenn.edu

Gregory Alfaro

2156622902greg.alfaro@pennmedicine.upenn.edu

Locations

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Gregory Alfaro

215-662-2902greg.alfaro@pennmedicine.upenn.edu

Principal Investigator:

Marina Cuchel, MD, PhD

More Information

Sponsor

University of Pennsylvania

Last update posted

May 6, 2026

Last verified

May, 2026

Keywords

  • Renal Disease
  • LCAT Deficiency
  • Familial LCAT Deficiency
  • FLD (Familial LCAT Deficiency)
  • Fish Eye Disease
  • FED (Fish Eye Disease)
  • Lipoprotein X
  • LpX (Lipoprotein X)
  • Cardiovascular Disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-05-06.